Disease
ADAbs + (n=25) ADAbs – (n=52)
p
Age, years
RA SpA CD 55.5 42.85 41.17 51.64 42.9 38.42 NS NS NS
Sex ratio
RA SpA CD 0.2 3.3 1 0.3 5.6 1.3 NS NS NS
BMI, kg/m2 (mean ± SD)
RA SpA CD 33 ± 1.2 22 ± 0.8 21.8 ± 0.3 26.5 ± 1.7 19.71 ± 0.9 20.58 ± 1.3 0.04 NS NS
Mean age at disease onset, years (mean ± SD)
RA SpA CD 39.33 ± 3.5 31.23 ± 2.8 30.83 ± 1.9 36.82 ± 2.8 33.25 ± 0.6 28 ± 3.1 NS NS NS
Disease duration, years (mean ± SD) RA SpA CD 9.08 ± 3.2 7.3 ± 2.1 17.17 ± 4.2 3.05 ± 1.1 6.3 ± 1.9 23.14 ± 4.8 NS NS NS
Duration of TNF alpha blockers therapy, months (mean ± SD)
RA SpA CD 51.83 ± 7.9 26.46 ± 6.9 5.17 ± 1.1 32.36 ± 11.2 39.9 ± 9.9 4.4 ± 1.3 NS NS NS
Concomitant use of MTX, n
RA SpA CD 9 5 0 12 6 3 NS NS 0.04
Mean dose of MTX, mg/week
RA SpA CD 10 ± 2.5 15 ± 2.3 13.5 ± 2.8 16.5 ± 2.9 20 0.04 NS 0.005
Concomitant use of AZA, n
RA SpA CD 0 0 12 0 0 21 - - NS
Mean dose of AZA, mg/kg/day
RA SpA CD 0 0 2,5 ± 0.9 0 0 2 ± 0.2 - - NS